Clinical Trials & Research
Many of today's most effective standard treatments are based on the results of previous clinical studies, and many cancer patients are now living longer because of progress made through clinical trials. Clinical trials offer high quality cancer care and also allow patients the opportunity to advance scientific knowledge and help future patients. Ongoing research is essential in the fight against cancer, and it is one of the major objectives of the Edwards Comprehensive Cancer Center.
The Charles H. McKown, Jr., MD, Translational Genomic Research Institute (TGRI), which is housed on the third floor of the Edwards Comprehensive Cancer Center, offers the appropriate environment for performing leading-edge cancer research and conducting clinical trials that are helping to shape the future of cancer research — and not just in Huntington.
ChemoID®, the first chemosensitivity assay against both cancer stem cells and bulk of tumor cells for patients, was developed by researchers, physicians and scientists working in the Translational Genomic Research Institute (TGRI) and it is now in use in the United States as well as other countries around the world.
“The goal of cancer research at the TGRI is to directly affect the disease outcome by taking innovative technologies and novel drugs from the bench to the bedside,” said Dr. Pier Paolo Claudio, who was instrumental in developing ChemoID®. “This approach saves lives and reduces healthcare costs. The research we conduct at the TGRI in collaboration with the Edwards Comprehensive Cancer Center will have a far-reaching impact on people suffering with cancer around the world.”
Clinical trials currently available
|CA204-006||A Phase 3, Randomized, Open Label trial of Lenalidomide/dexamethasone With or without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma.|
|E2905||Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia.|
- Page last updated: Jul 3, 2014